Viral Vector Manufacturing

VectorBuilder has extensive expertise in producing various types of viral vectors for cell and gene therapy development. We offer these at various scales and quality attributes to meet the full range of demands along the gene therapy drug development pipeline. Our team has established and validated platform technologies for large-scale GMP manufacturing of adeno-associated virus (AAV) and lentivirus, and we also have the expertise and capacity for manufacturing other types of viral vectors such as adenovirus, MMLV, herpes simplex virus (HSV), and vesicular stomatitis virus (VSV).
Highlights
Experts in Virus Packaging Proprietary technologies optimized to achieve the highest titer and potency at any scale.
Highest Quality and Consistency State-of-the-art GMP facilities and equipment providing the highest purity and consistency.Grades of Viral Vectors Offered
We produce viruses in several grades to cover a full range of downstream applications including drug discovery research, preclinical studies, clinical trials, and commercialization.

- Suitable for basic research, such as studies in gene function and regulation, and drug discovery studies
- Produced in conventional cell culture facilities with stringent QC

- Suitable for preclinical studies (e.g. animal testing of drug safety and metabolism)
- Produced in PAS or GMP facilities in a manner that adopts key features of GMP guidelines
- Can be produced under antibiotic-free and animal component-free conditions

- Suitable for preclinical studies, clinical studies, and commercialization
- Produced in our certified GMP suite with strict adherence to GMP guidelines
- Includes comprehensive and customizable QC assays and batch release report
Comparison of different grades of virus
| Research-Grade | GMP-Like | GMP-Grade | |
|---|---|---|---|
| Applications | Basic research, drug discovery, and preclinical studies | Preclinical studies such as animal testing of drug safety and metabolism | Preclinical studies, clinical studies, and commercialization |
| Production scales | 5x1010 to 1014 GC per batch | 5x1013 to 1017 GC per batch | 1014 to 1017 GC per batch |
| Turnaround time | 10-50 days | 4-5 months | 6-12 months |
| Production site | In parallel production in standard BSL-2 laboratory | Produced in segregated BSL-2 production suites | Produced in certified GMP suites (BSL-2) |
| Quality system | ISO9001 | ISO9001 while adopting key features of GMP manufacturing | ICH quality guidelines for GMP manufacturing |
| Document control and traceability | No | Yes | Full traceability |
| Vector characterization | RE digestion, insert sequencing | RE digestion, full-length sequencing | RE digestion, full-length sequencing |
| Process development | No | Performed on a case-by-case basis depending on individual project needs | Yes |
| Cell banking | No | Available upon request | Yes |
| Antibiotic-free | No | Available upon request | Yes |
| Animal component-free | No | Available upon request for suspension culture | For suspension culture |
| Purification | Ultracentrifugation | Ultracentrifugation, affinity purification, IEX purification, mixed-mode chromatography | Ultracentrifugation, affinity purification, IEX purification, mixed-mode chromatography |
| QC and release tests | Titer measurement, SDS-PAGE, endotoxin detection, sterility testing, mycoplasma detection, etc. | Performed on a case-by-case basis depending on individual project needs | Full panel QC assays, analytical development upon individual project needs |
| Aseptic fill/finish | No | Available upon request | Yes |
| Storage of retain sample | Available upon request | Available upon request | Yes |
| Document deliverable | COA | 1. COA 2. Manufacturing summary 3. TSE/BSE statement upon request |
1. COA 2. TSE/BSE statement 3. CTD documents 4. Others (BMR etc.) upon request |
| Research-Grade | GMP-Like | GMP-Grade | |
|---|---|---|---|
| Applications | Basic research, drug discovery, preclinical studies | Preclinical studies such as animal testing of drug safety and metabolism | Preclinical studies, clinical studies, and commercialization |
| Production scales | >2.5x107 TU | 109 to 1012 TU per batch | 5x109 to 1012 TU per batch |
| Turnaround time | 8-16 days | 4-5 months | 6-12 months |
| Production site | In parallel production in standard BSL-2 laboratory | Produced in segregated BSL-2 production suites | Produced in certified GMP suites (BSL-2) |
| Quality system | ISO9001 | ISO9001 while adopting key features of GMP manufacturing | ICH quality guidelines for GMP manufacturing |
| Document control and traceability | No | Yes | Full traceability |
| Vector characterization | RE digestion, insert sequencing | RE digestion, full-length sequencing | RE digestion, full-length sequencing |
| Process development | No | Performed on a case-by-case basis depending on individual project needs | Yes |
| Cell banking | No | Available upon request | Yes |
| Antibiotic-free | No | Available upon request | Yes |
| Animal component-free | No | Available upon request for suspension culture | For suspension culture |
| Purification | Ultracentrifugation | Ultracentrifugation, affinity purification, IEX purification, mixed-mode chromatography | Ultracentrifugation, affinity purification, IEX purification, mixed-mode chromatography |
| QC and release tests | Titer measurement, sterility testing, mycoplasma detection, etc. | Performed on a case-by-case basis depending on individual project needs | Full panel QC assays, analytical development upon individual project needs |
| Aseptic fill/finish | No | Available upon request | Yes |
| Storage of retain sample | Available upon request | Available upon request | Yes |
| Document deliverable | COA | 1. COA 2. Manufacturing summary 3. TSE/BSE statement upon request |
1. COA 2. TSE/BSE statement 3. CTD documents 4. Others (BMR etc.) upon request |
Workflow for GMP Production of Viral Vectors
VectorBuilder strives to deliver products of the highest quality on time. Here is a typical GMP production workflow of viral vectors:
Characterization
Development
Banking
Production
Run
- RE digestion
- Sequencing
- Cell line
development - USP/DSP
- Analytical
development
- RCB
- MCB
- WCB
- Segregated
suite
(GMP-like) - GMP suite
(GMP-grade)
- Closed system
- Fill/finish
- General/physical
properties - Identity
- Purity
- Safety
Platform Technologies
AAVs are packaged in HEK293 cells under either adherent conditions (multi-layer flasks or fixed-bed bioreactors) or serum-free suspension conditions (up to 200 L single-use bioreactors). Upon request, we can also package AAV in suspension Sf9 insect cells. We are capable of production scales reaching up to 1017 GC AAV per batch.
(Multi-layer flasks,
fixed-bed bioreactors)
(Single-use bioreactors)
(PEI, calcium
phosphate
lysis
concentration
(TFF)
(Chromatography)
(TFF, sterile
filtration, fill/finish)
Lentivirus packaging (2nd or 3rd generation, pseudotyped with VSV-G or other viral surface proteins) is performed in HEK293 cells under either adherent conditions (multi-layer flasks or fixed-bed bioreactors) or serum-free suspension conditions (up to 200 L single-use bioreactors). We are capable of production scales of up to 1012 TU per batch.
(Multi-layer flasks,
fixed-bed bioreactors)
(Single-use bioreactors)
(PEI, calcium
phosphate
concentration
(TFF)
(Chromatography)
(TFF, sterile
filtration, fill/finish)
For more information on our manufacturing platform and/or GMP capabilities, contact the VectorBuilder service team.
Analytical Methods
Quality control assays
The table below summarizes the default QC assays (marked with ✓) for the release of GMP-like and GMP-grade viral vectors. Optional QC assays are performed depending on individual project needs.
| Attribute | QC Assay | GMP-Like | GMP-Grade | |
|---|---|---|---|---|
| General/Physical Properties | Osmolality | Freezing point depression | Optional | ✓ |
| pH | pH meter | ✓ | ✓ | |
| Particulate matter | Light obscuration particle count test | Optional | ✓ | |
| Appearance | Visual inspection | Optional | ✓ | |
| Extractable volume | Direct measurement | Optional | ✓ | |
| Physical titer | qPCR | ✓ | ✓ | |
| ddPCR | Optional | ✓ | ||
| ELISA | ✓ | ✓ | ||
| Infectious titer | TCID50 | Optional | Optional | |
| Potency | mRNA transcription | RT-qPCR | Optional | ✓ |
| RT-ddPCR | Optional | Optional | ||
| Protein expression | Flow cytometry (FCM) | Optional | Optional | |
| Identity | Full-length plasmid sequence | Sanger sequencing | ✓ | ✓ |
| NGS | Optional | Optional | ||
| Third-generation sequencing | Optional | Optional | ||
| Purity | Capsid protein purity | SDS-PAGE with silver staining | ✓ | ✓ |
| Empty capsid ratio | Transmission electron microscopy (TEM) | Optional | Optional | |
| Mass photometry (MP) | ✓ | ✓ | ||
| Analytical ultracentrifugation (AUC) | Optional | ✓ | ||
| Charge detection mass spectrometry (CDMS) | Optional | Optional | ||
| Aggregation | Dynamic light scattering (DLS) | Optional | Optional | |
| Size exclusion chromatography (SEC) | Optional | ✓ | ||
| Genome integrity | Alkaline gel electrophoresis | ✓ | ✓ | |
| Process-Related Impurity | Residual plasmid DNA | qPCR | ✓ | ✓ |
| ddPCR | Optional | Optional | ||
| Residual host cell DNA | qPCR | ✓ | ✓ | |
| Residual E1A sequence | qPCR | ✓ | ✓ | |
| Residual host cell DNA fragment size | Capillary electrophoresis (CE) | Optional | ✓ | |
| Residual host cell proteins | ELISA | ✓ | ✓ | |
| Residual Benzonase | ELISA | ✓ | ✓ | |
| Residual affinity ligand | HPLC | Optional | Optional | |
| Residual transfection reagent | HPLC | Optional | Optional | |
| Residual ultracentrifugation agent | HPLC | Optional | ✓ | |
| Residual detergent | HPLC | Optional | Optional | |
| Product-Related Impurity | Replication competent AAV | qPCR | Optional | ✓ |
| Safety | Sterility | Direct inoculation | Optional | Optional |
| Membrane filtration sterility test | ✓ | ✓ | ||
| Endotoxin | Kinetic chromogenic assay (KCA) | ✓ | ✓ | |
| Mycoplasma | DNA staining | ✓ | Optional | |
| qPCR | ✓ | Optional | ||
| Direct culture and indicator cell culture | Optional | ✓ | ||
| Adventitious virus testing | Cell culture (using MRC-5, VERO, and HEK293 cells) | Optional | ✓ | |
| Documentation | - | - |
1. COA
2. Manufacturing summary
3. TSE/BSE certificate upon request
|
1. COA
2. TSE/BSE certificate
3. CTD documents
4. Others (BMR, etc.) upon request
|
| Attribute | QC Assay | GMP-Like | GMP-Grade | |
|---|---|---|---|---|
| General/Physical Properties | Osmolality | Freezing point depression | Optional | ✓ |
| pH | pH meter | ✓ | ✓ | |
| Particulate matter | Light obscuration particle count test | Optional | ✓ | |
| Appearance | Visual inspection | Optional | ✓ | |
| Extractable volume | Direct measurement | Optional | ✓ | |
| Physical titer | RT-qPCR | Optional | ✓ | |
| ELISA | ✓ | ✓ | ||
| Functional titer | qPCR | ✓ | ✓ | |
| Flow cytometry (FCM) | Optional | ✓ | ||
| Infectious titer | TCID50 | Optional | Optional | |
| Potency | mRNA transcription | RT-ddPCR | Optional | Optional |
| Protein expression | Flow cytometry (FCM) | Optional | Optional | |
| Identity | Full-length plasmid sequence | Sanger sequencing | ✓ | ✓ |
| NGS | Optional | Optional | ||
| Third-generation sequencing | Optional | Optional | ||
| Purity | Aggregation | Dynamic light scattering (DLS) | Optional | Optional |
| Process-Related Impurity | Residual plasmid DNA | qPCR | ✓ | ✓ |
| ddPCR | Optional | Optional | ||
| Residual host cell DNA | qPCR | ✓ | ✓ | |
| Residual E1A sequence | qPCR | ✓ | ✓ | |
| Residual SV40 LTA sequence | qPCR | ✓ | ✓ | |
| Residual host cell DNA fragment size | Capillary electrophoresis (CE) | Optional | ✓ | |
| Residual host cell proteins | ELISA | ✓ | ✓ | |
| Residual Benzonase | ELISA | ✓ | ✓ | |
| Residual affinity ligand | HPLC | Optional | Optional | |
| Residual transfection reagent | HPLC | Optional | Optional | |
| Residual detergent | HPLC | Optional | Optional | |
| Product-Related Impurity | Replication competent lentivirus | Cell culture | Optional | ✓ |
| Safety | Sterility | Direct inoculation | Optional | Optional |
| Membrane filtration sterility test | ✓ | ✓ | ||
| Endotoxin | Kinetic chromogenic assay (KCA) | ✓ | ✓ | |
| Mycoplasma | DNA staining | ✓ | Optional | |
| qPCR | ✓ | Optional | ||
| Direct culture and indicator cell culture | Optional | ✓ | ||
| Adventitious virus testing | Cell culture (using MRC-5, VERO, and HEK293 cells) | Optional | ✓ | |
| Documentation | - | - |
1. COA
2.Manufacturing summary
3.TSE/BSE certificate upon request
|
1. COA
2. TSE/BSE certificate
3. CTD documents
4. Others (BMR, etc.) upon request
|
Additional QC services not listed above may be provided upon request. Please contact our service team for more details.
Stability studies
Drug stability studies are performed following ICH guidelines. Forced degradation studies are performed to evaluate the influence of light, temperature, pH, etc., on the quality attributes of the viral vector DNA.
Our Facilities
VectorBuilder currently has about 100,000 ft2 of modern GMP-compliant facilities with advanced designs and state-of-the-art equipment meeting GMP regulations of US, EU, Japan, China, and PIC/S. Our facilities comply with ICH guidelines and are suitable for GMP production for Phase I/II/III clinical trials.
- Process & Analytical
Development Suites - GMP Manufacturing
Suites - Fill/finish Suites
- QC Laboratories
- GMP Warehouse

We have multiple GMP suites totaling 8,400 ft2 for PD/pilot runs. All BSL-2 certified areas are set up with Grade A BSC in Grade C environment.

Our suites are designed for manufacturing plasmid, viral vector, and cell line production at various scales. Each suite is equipped with independent airflow. Our suites contain Grade A BSC in Grade B/C environment and are BSL-2 certified.

Our automated filling system is installed within a Grade A isolator in a Grade C environment.

Our independent QC laboratories consist of multiple lab suites totaling 9,500 ft2 for a wide range of QC assays.

We have 6,500 ft2 of ICH-compliant warehouse space for product storage and monitoring.